© 2012

  Leducq-Network for Vascular MicroRNAs (MIRVAD) 

Vascular system assessed by microCT

picture kindly provided by Zhen Zhuang, Yale University

The mission of Fondation Leducq ( is to improve human health through international efforts to combat cardiovascular and neurovascular disease. MIRVAD has been funded by the Leducq Fondation from 2013-2018 to study the role of microRNAs in vascular diseases. MicroRNAs (miRNAs) are small non-coding RNAs that modulate gene expression. In the emerging field of vascular miRNA research, the members of this network have identified several intracellular miRNAs regulating vascular biology that play key roles in vascularization, atherosclerosis and vascular remodeling.


Surprisingly, the cellular source and functional significance of circulating miRNAs in vascular disease are still unknown. Determining the importance of miRNAs as novel cell/cell communicators may allow for the development of biomarker profiles based on circulating mi-RNAs. The central aim of this project, however, is to target selected miRNAs as potential therapies for vascular diseases. With the finding that newly-discovered non-coding RNAs are associated with vascularization, atherosclerosis and aneurysm formation, researchers now believe that vascular miRNAs are central targets for therapeutic manipulation. The network will focus on new and previously identified candidate miRNAs as potential therapies for these three vascular disease areas using genetically modified animal models and pharmacologic strategies. Therapeutic approaches to silence pathologic miRNAs will be tested in clinically relevant, large animal models as a pathway to first-in-man clinical trials to treat human disease.


The diverse and synergistic talents of the investigative team will provide an unprecedented, comprehensive approach towards understanding the biological role and therapeutic potential of miRNAs. This networking and training strategy on vascular miRNAs will significantly contribute to future diagnostic and therapeutic benefits for patients with cardiovascular diseases.